General Overview and Highlights of the

Slides:



Advertisements
Similar presentations
Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.
Advertisements

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Stroke prevention in atrial fibrillation
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
AF and NOACs An UPDATE JULY 2014
The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG Case discussion The patient caught between.
How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,
Managing Patients Who Cannot Take Anticoagulants Kenneth W. Mahaffey, MD, FACC Professor of Medicine, Cardiology Faculty Associate Director, DCRI Director,
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Challenges with Drug Administration Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed? Dominick J. Angiolillo,
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
General Overview and Highlights of the
The patient with atrial fibrillation who needs PCI
The Primary and Secondary Prevention of Cardiovascular Disease
CHU TIMONE, Marseille, FR
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Stent Thrombosis and Optimal Duration of DAPT
Management of Patients on Chronic Oral Anticoagulant Therapy
Adnan K. Chhatriwalla, MD Saint-Luke’s Mid America Heart Institute
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
When to Switch and How to Switch
Updates From NOTION: The First All-Comer TAVR Trial
Role of LAA Occlusion in Patients With Atrial Fibrillation After PCI Marco Mennuni, MD Interventional Cardiologist Hopital Europeen George Pompidou,
MCV Campus Ginger Edwards.
CRT 2017: Putting LAA closure in the age of DOACs into perspective
Harvard Medical School C. Michael Gibson, M.S., M.D.
When should aspirin be dropped from triple therapy?
You can never be too Thin…. An Update on NOACs
How Do We Incorporate Patient Perspectives Into Clinical Trial Design?
Should We Preload STEMI Patients with Antiplatelet Therapy?
Antithrombotic Therapy in Atrial Fibrillation
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
Short versus Long DAPT Studies – An Academic View
Polypharmacy Anticoagulation: AF meets PCI
Antithrombotic Therapy in Peripheral Artery Disease
Philip Urban, Philippe Garot, Damras Tresukosol,
Department of Cardiology Bern University Hospital
ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.
No evidence that AF type significantly impacts stroke risk
on behalf of the RE-DUAL PCI Steering Committee and Investigators
The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor
The ANTARCTIC investigators
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Antithrombotic Therapy in AF patients undergoing PCI
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Nat. Rev. Cardiol. doi: /nrcardio
Glenn N. Levine et al. JACC 2016;68:
Selecting NOACs for High-Risk Patients
NOACS: Emerging data in ACS/IHD
Section F: Clinical guidelines
How and why this study may change my practice ?
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Why I Prefer Ticagrelor
Which NOAC and When for Stroke Prevention in AF?
What oral antiplatelet therapy would you choose?
Nat. Rev. Cardiol. doi: /nrcardio
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.
Presenter Disclosure Information
Presentation transcript:

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patients with ACS or PCI Dominick J. Angiolillo, MD, PhD Professor of Medicine Medical Director - Cardiovascular Research Program Director – Interventional Cardiology Fellowship University of Florida College of Medicine - Jacksonville

Presenter Disclosure Information Name: Dominick J Angiolillo Within the past 12 months, the presenter or their spouse/partner have had a financial interest/arrangement or affiliation with the organization listed below. Received payment as an individual for: a) Consulting fee or honorarium from Amgen, Bayer, Chiesi, Sanofi, Eli Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Merck, Abbott Vascular, Pfizer, and PLx Pharma; b) Honorarium for participation in review activities (DSMB member) from CeloNova, Johnson & Johnson, St. Jude, and Sunovion. c) Honorarium from the American Board of Internal Medicine (Interventional Cardiology Subspecialty Exam Writing Committee Member) Institutional payments for: a) Grant support industry: from Amgen, Glaxo-Smith-Kline, Eli Lilly, Daiichi-Sankyo, The Medicines Company, AstraZeneca, Janssen Pharmaceuticals, Inc., Osprey Medical, Inc., Novartis, CSL Behring, and Gilead. b) Grant in gift: Spartan; Scott R. MacKenzie Foundation c) Federal agency: NIH

AF + PCI: Dimension of the Problem AF is the most common cardiac arrhythmia occurring in 1- 2% of the general population, with a prevalence that increases with age. Among AF patients at moderate-to-high risk for cardioembolic events, the use of chronic OAC is the mainstay of stroke prevention. The prevalence of CAD also increases with age and coexists in 20- 30% of AF patients; ~ 5–7% of PCI patients, who are routinely treated with DAPT, also have AF or other indications for OAC. These estimates are expected to increase as the global burden of AF increases, driven in large part to the aging population. These observations raise an important clinical problem regarding the optimal antithrombotic management of patients undergoing PCI who also have AF. Currently, there are limited evidenced-based data on the optimal antithrombotic treatment regimen of PCI patients who also require OAC due to AF, and Guidelines provide limited insights on the management of these high-risk patients.

The 2011 North American Perspective Faxon DP et al. Circ Cardiovasc Interv. 2011;4:522-534

AF + PCI: A North American Perspective – 2016 Update Dominick J. Angiolillo, MD, PhD; Shaun G. Goodman, MD; Deepak L. Bhatt, MD, MPH; John W. Eikelboom, MD; Matthew J. Price, MD; David J. Moliterno, MD; Christopher P. Cannon, MD; Jean-Francois Tanguay, MD; Christopher B. Granger, MD; Laura Mauri, MD; David R. Holmes, MD; C. Michael Gibson, MD; David P. Faxon, MD

AF + PCI: A North American Perspective – 2016 Update The Challenge: Discerning the choice of antithrombotic therapy Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Consensus Document Objectives Provide current views on: embolic/stroke risk ischemic/thrombotic cardiac risk bleeding risk Describe the recent advances in antithrombotic (antiplatelets and anticoagulants) pharmacology, stent designs, and clinical trials relevant to the field. Provide expert consensus derived recommendations, using a pragmatic approach, on the management of patients with AF undergoing PCI. Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Defining the need for chronic OAC CHA2DS2-VASc Score CHF/LV dysfunction (LVEF ≤40%) 1 Stroke/TIA/TE 2 Hypertension 1 Vascular disease (prior MI, PAD, or aortic) 1 Age ≥75 years 2 Age 65–74 years 1 Diabetes mellitus 1 Sex category (ie, female sex) 1 Low risk (no antithrombotic therapy) defined as CHA2DS2-VASc of 0 in males (“age <65 and lone AF”) CHA2DS2-VASc of 1 in females (“age <65 and lone AF”) Lip GY, et al. Chest. 2010;137:263–272

The North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI

AF + PCI: A North American Perspective – 2016 Update Pre-procedural Considerations 1. Define “Appropriateness” for PCI. - Consider Appropriateness Criteria for PCI - Nothing wrong with trying medical therapy first - Once stent is implanted: point of no return! A U I Patel M et al JACC 2009

AF + PCI: A North American Perspective – 2016 Update Pre-procedural Considerations 2. Ischemic/thrombotic & bleeding risk stratification Levine G et al. Circulation 2016

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI

The North American Perspective – 2016 Update Procedural Considerations 1. Vascular Access: Radial Consistently shown to be associated with less bleeding Mortality benefit 2. Stent choice: New generation DES - New generation DES: better safety even compared with BMS; typically AF patients also have more complex CAD - BMS: if considered, should only be for simple lesions (short length/ large diameter) - BVS: high early ST rates which increase with lesion complexity (some advocate more potent antithrombotic therapy) - Other new stent platforms (e.g., DCS): not available in the US

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI Whenever possible (i.e., elective / non-emergent procedures), a brief period of wash- out from the anticoagulant effect of OAC is preferable. For patients on a VKA: INR to be preferably ≤2.0 when using a radial approach (recommended) and ≤ 1.5 if femoral approach is used. Patients on a NOAC: withhold therapy for 24 hours (or 48 hours for patients with impaired renal function with dabigatran) irrespective of vascular access site. Although patients with stable CAD can forgo bridging with parenteral anticoagulation, this should be considered for patients presenting with an ACS.

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI Given the current controversies over the net benefits of bivalirudin over other antithrombotic treatment regimens as well as differences in practice patterns among interventionalists, this expert consensus does not recommend a specific parenteral antithrombin agent over another. However, bivalirudin appears to be a reasonable treatment option in patients at higher risk of bleeding, particularly in those presenting with ACS and if a femoral approach is being used.

AF + PCI: A North American Perspective – 2016 Update The choice of OAC (VKA or NOAC) is at the discretion of the treating physician, with patients informed on the risk-benefit profiles of each agent based on available data. Continuing with the same OAC after PCI may be reasonable, particularly if the patient has been compliant and has not experienced complications. If a VKA is chosen, maintain an INR in the 2.0-3.0 range (ideally between 2.0–2.5). A NOAC at lowest therapeutic dose effective for stroke prevention should be preferred over a VKA in patients unable to have their INR routinely monitored or are unable to maintain INR in the therapeutic range. A recommendation on use of doses lower than the full anticoagulant dose of a specific NOAC cannot be provided until further data become available.

The North American Perspective – 2016 Update This expert consensus recommends that the duration of DAPT in AF patients treated with stents also on OAC should not extend to a full 12 months and to consider SAPT starting within the first 6-months (0 to 6 months post-stenting depending on the ischemic/thrombotic and bleeding risk profile) for up to 12 months. This group consensus recommends that dropping aspirin rather than a P2Y12 receptor inhibitor should be considered (favoring the use of clopidogrel and avoiding prasugrel or ticagrelor).

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI Discontinuation of one antiplatelet agent should be considered 1-3 months after PCI, this may occur sooner (including immediately after PCI) or later (but not beyond 6 months) according to the ischemic/thrombotic and bleeding risk profiles of the patient. Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Aspirin might be no longer needed after 12 months in AF patients with stable CAD on VKA Age ad gender adj. HR (95% CI) No difference In CV death/MI/CVA in patients treated with VKA + APT versus patients treated with VKA alone adj. HR: 1.15 95% CI 0.58-2.27 p=0.697 SAT Reference DAPT 1.58 [0.72-3.47] VKA+SAT 7.30 [3.91-13.64] VKA alone 1.69 [0.39-7.30] 0.1 1 100 CORONOR – 4,184 patients on oral anticoagulation with stable (>12 mo) CAD Hamon M, et al. J Am Coll Cardiol 2014;64:1430–6

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI Balanced thrombotic / bleeding risk Shorter (e.g., 1 month) and longer (e.g., 3 months) DAPT duration should be considered in patients treated with BMS and DES, respectively. Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI High bleeding / low thrombotic risk Discontinuation of one antiplatelet agent may be considered immediately after PCI if patients at very-high bleeding risk Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI High thrombotic / low bleeding risk Shorter (e.g., 3 month) and longer (e.g., 6 months) DAPT duration should be considered in patients treated with BMS and DES, respectively. Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Pragmatic algorithm for the management of AF patients requiring OAC undergoing PCI More frequent follow-up visits. Don’t leave in the exclusive care of PCP. Choice/duration of antithrombotic therapy may change over time depending on clinical evolution. At 1-year post-PCI need to evaluate need to continue with any antiplatelet agent based on bleeding/thrombotic risk.

AF + PCI: A North American Perspective – 2016 Update Peri- and post-procedural Considerations Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Ongoing trials of NOACs in AF patients undergoing PCI AHA 2016 NOAC wins ESC 2017 ? Angiolillo DJ et al. Circ Cardiovasc Interv. 2016

AF + PCI: A North American Perspective – 2016 Update Stay tuned for 2017 Update Dominick J. Angiolillo, MD, PhD; Shaun G. Goodman, MD; Deepak L. Bhatt, MD, MPH; John W. Eikelboom, MD; Matthew J. Price, MD; David J. Moliterno, MD; Christopher P. Cannon, MD; Jean-Francois Tanguay, MD; Christopher B. Granger, MD; Laura Mauri, MD; David R. Holmes, MD; C. Michael Gibson, MD; David P. Faxon, MD